TSP-1-Mediated Induction of T Regulatory Cell by Adipose-Derived Mesenchymal Stem Cells: A Mechanism of Immunosuppression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance.Cancer metastasis reviews · 2024
   Review
2. Preliminary studies of constructing a tissue-engineered lamellar corneal graft by culturing mesenchymal stem cells onto decellularized corneal matrix.International journal of ophthalmology · 2021
   Article
3. Emerging role of tumor cell plasticity in modifying therapeutic response.Signal transduction and targeted therapy · 2020
   Review

Corrections and comments

• Comment on
  Adipose-Derived Stem Cells Ameliorate Experimental Murine Colitis via TSP-1-Dependent Activation of Latent TGF-β.2017

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as